ISSN 2394-5125
 

Research Article 


Intravenous Immunoglobulin for Alzheimer's Disease Treatment

Shaurab Jha, Neeraj Jha, Ankur Sharma.

Abstract
Alzheimer's syndrome (Alzheimer's disease), in many nations, is a debilitating neurospecies that become rapidly widespread. Amyloide plaques and neurofibrillary pinches accompanied by overall neuronal loss are characterized inside brains of AD persons. Immune-mediated neurological disorders, like Guillain-Barre's and Myasthenia Gravis Syndromes, often have intravenous immunoblobulin (IVIg). Human blood and blood IVIG produce naturally arising anti-Aβ antibodies (Nabs-Aβ), potentially decreasing the likelihood of Alzheimer's disease. The amyloid-β peptide (Aβ) is applied to amyloid plaques inside AD's brains. As a consequence of this, Aβ is targeted by many treatments. There are symptomatic medications currently available but the course of the underlying disease is not changed. A phase III trial with multicenter approach is currently under way to decide whether or not present treatment may enhance cognitive debits in mild to modest Alzheimer's disease. Our knowledge of AD pathogenesis has progressed substantively while no treatment for AD has yet been identified. This discovery contributed to the production of several promising compounds at different levels of clinical research. The purpose of this work is to analyze the pathogenic role and immunotherapy activities of amyloid in AD to date.

Key words: Alzheimers disease, Neurodegenerative, Immunotherapy, Intravenous immunoblobulin, Antibodies.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Shaurab Jha
Articles by Neeraj Jha
Articles by Ankur Sharma
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Shaurab Jha, Neeraj Jha, Ankur Sharma. Intravenous Immunoglobulin for Alzheimer's Disease Treatment. JCR. 2020; 7(9): 1377-1381. doi:10.31838/jcr.07.09.254


Web Style

Shaurab Jha, Neeraj Jha, Ankur Sharma. Intravenous Immunoglobulin for Alzheimer's Disease Treatment. http://www.jcreview.com/?mno=120655 [Access: May 30, 2021]. doi:10.31838/jcr.07.09.254


AMA (American Medical Association) Style

Shaurab Jha, Neeraj Jha, Ankur Sharma. Intravenous Immunoglobulin for Alzheimer's Disease Treatment. JCR. 2020; 7(9): 1377-1381. doi:10.31838/jcr.07.09.254



Vancouver/ICMJE Style

Shaurab Jha, Neeraj Jha, Ankur Sharma. Intravenous Immunoglobulin for Alzheimer's Disease Treatment. JCR. (2020), [cited May 30, 2021]; 7(9): 1377-1381. doi:10.31838/jcr.07.09.254



Harvard Style

Shaurab Jha, Neeraj Jha, Ankur Sharma (2020) Intravenous Immunoglobulin for Alzheimer's Disease Treatment. JCR, 7 (9), 1377-1381. doi:10.31838/jcr.07.09.254



Turabian Style

Shaurab Jha, Neeraj Jha, Ankur Sharma. 2020. Intravenous Immunoglobulin for Alzheimer's Disease Treatment. Journal of Critical Reviews, 7 (9), 1377-1381. doi:10.31838/jcr.07.09.254



Chicago Style

Shaurab Jha, Neeraj Jha, Ankur Sharma. "Intravenous Immunoglobulin for Alzheimer's Disease Treatment." Journal of Critical Reviews 7 (2020), 1377-1381. doi:10.31838/jcr.07.09.254



MLA (The Modern Language Association) Style

Shaurab Jha, Neeraj Jha, Ankur Sharma. "Intravenous Immunoglobulin for Alzheimer's Disease Treatment." Journal of Critical Reviews 7.9 (2020), 1377-1381. Print. doi:10.31838/jcr.07.09.254



APA (American Psychological Association) Style

Shaurab Jha, Neeraj Jha, Ankur Sharma (2020) Intravenous Immunoglobulin for Alzheimer's Disease Treatment. Journal of Critical Reviews, 7 (9), 1377-1381. doi:10.31838/jcr.07.09.254